---
document_datetime: 2025-12-02 05:04:45
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/recarbrio.html
document_name: recarbrio.html
version: success
processing_time: 0.108328
conversion_datetime: 2025-12-27 23:51:27.135437
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Recarbrio

[RSS](/en/individual-human-medicine.xml/67280)

##### Authorised

This medicine is authorised for use in the European Union

imipenem / cilastatin / relebactam Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Recarbrio](#news-on)
- [More information on Recarbrio](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Recarbrio is an antibiotic for treating adults with the following infections:

- lung infections caught in hospital (hospital-acquired pneumonia), including ventilator-associated pneumonia (pneumonia caught while on a ventilator, which is a machine that helps a patient to breathe);
- infection that has spread into the blood (bacteraemia) as a likely complication of hospital-acquired pneumonia or ventilator-associated pneumonia;
- infections caused by bacteria classed as aerobic Gram-negative bacteria when other treatments might not work.

Official guidance on the appropriate use of antibiotics should be considered when using the medicine.

Recarbrio contains the active substances imipenem, cilastatin and relebactam.

Expand section

Collapse section

## How is Recarbrio used?

Recarbrio can only be obtained with a prescription and it should be used only after consulting a doctor with experience of managing infectious diseases.

Recarbrio is given by infusion (drip) into a vein over 30 minutes. It is given every 6 hours for 5 to 14 days, depending on the nature of the infection.

For more information about using Recarbrio, see the package leaflet or contact your doctor or pharmacist.

## How does Recarbrio work?

One of the active substances in Recarbrio, imipenem, kills bacteria and the other two, cilastatin and relebactam, increase imipenem's effectiveness in different ways.

Imipenem interferes with bacterial proteins that are important for building the bacterial cell wall. This results in defective cell walls that collapse and cause the bacteria to die. Imipenem is quickly broken down by the kidneys and the cilastatin in Recarbrio prevents this breakdown and so allows imipenem to work for longer. The third active substance, relebactam, blocks enzymes in the bacteria called beta-lactamases. These enzymes break down antibiotics such as imipenem and stop them working.

## What benefits of Recarbrio have been shown in studies?

In a main study in 47 adults with infections caused by Gram-negative bacteria, 71% of patients treated with Recarbrio had a favourable outcome (based on their symptoms and test results) compared with 70% of patients treated with another combination (colistin, imipenem and cilastatin). Patients in this study had serious infections that were resistant to treatment with imipenem plus cilastatin. Patients were treated for hospital-acquired pneumonia, complicated intra-abdominal infection (infection that has spread in the belly with swelling and build-up of pus) and complicated urinary tract infection (infection extending beyond the bladder into the kidneys).

In a second main study involving 537 patients with hospital-acquired or ventilator-associated pneumonia, 61% of patients treated with Recarbrio were cured (assessed 7 to 14 days after the end of treatment) compared with 56% of patients treated with piperacillin and tazobactam (another antibiotic combination).

## What are the risks associated with Recarbrio?

The most common side effects with Recarbrio (which may affect up to 1 in 10 people) are diarrhoea and blood test results showing disturbances in liver enzymes (suggesting stress on the liver).

Recarbrio must not be used in patients who are hypersensitive (allergic) to imipenem and other carbapenem antibiotics (such as ertapenem and meropenem) or in patients who have had a severe allergic reaction to the broader class of beta-lactam antibiotics (such as penicillins and cephalosporins).

For the full list of side effects and restrictions of Recarbrio, see the package leaflet.

## Why is Recarbrio authorised in the EU?

There were too few patients in the main study of infections caused by Gram-negative bacteria to show conclusively that Recarbrio is effective against bacteria that have become resistant to imipenem. However, studies on how the medicine works in the body provided more evidence of its effectiveness. Recarbrio can therefore be useful when there is limited choice of treatment for bacterial infections resistant to imipenem and other carbapenem antibiotics.

The study in patients with hospital-acquired or ventilator-associated pneumonia found Recarbrio at least as effective as the antibiotic combination piperacillin with tazobactam. The European Medicines Agency noted that imipenem plus cilastatin is already authorised for treating bacteraemia linked to hospital-acquired or ventilator-associated pneumonia.

Recarbrio's side effects, which are similar to those of imipenem with cilastatin, are acceptable.

The Agency therefore decided that Recarbrio's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Recarbrio?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Recarbrio have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Recarbrio are continuously monitored. Side effects reported with Recarbrio are carefully evaluated and any necessary action taken to protect patients.

## Other information about Recarbrio

Recarbrio received a marketing authorisation valid throughout the EU on 13 February 2020.

Recarbrio : EPAR - Medicine overview

English (EN) (162.99 KB - PDF)

**First published:** 26/02/2020

**Last updated:** 19/02/2021

[View](/en/documents/overview/recarbrio-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-571)

български (BG) (182.75 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/bg/documents/overview/recarbrio-epar-medicine-overview_bg.pdf)

español (ES) (157.01 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/es/documents/overview/recarbrio-epar-medicine-overview_es.pdf)

čeština (CS) (169.12 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/cs/documents/overview/recarbrio-epar-medicine-overview_cs.pdf)

dansk (DA) (157.44 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/da/documents/overview/recarbrio-epar-medicine-overview_da.pdf)

Deutsch (DE) (160.7 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/de/documents/overview/recarbrio-epar-medicine-overview_de.pdf)

eesti keel (ET) (144.74 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/et/documents/overview/recarbrio-epar-medicine-overview_et.pdf)

ελληνικά (EL) (181.93 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/el/documents/overview/recarbrio-epar-medicine-overview_el.pdf)

français (FR) (158.19 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/fr/documents/overview/recarbrio-epar-medicine-overview_fr.pdf)

hrvatski (HR) (179.09 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/hr/documents/overview/recarbrio-epar-medicine-overview_hr.pdf)

italiano (IT) (156.24 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/it/documents/overview/recarbrio-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (185.8 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/lv/documents/overview/recarbrio-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (177.84 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/lt/documents/overview/recarbrio-epar-medicine-overview_lt.pdf)

magyar (HU) (178.13 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/hu/documents/overview/recarbrio-epar-medicine-overview_hu.pdf)

Malti (MT) (178.79 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/mt/documents/overview/recarbrio-epar-medicine-overview_mt.pdf)

Nederlands (NL) (158.09 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/nl/documents/overview/recarbrio-epar-medicine-overview_nl.pdf)

polski (PL) (171.41 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/pl/documents/overview/recarbrio-epar-medicine-overview_pl.pdf)

português (PT) (157.55 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/pt/documents/overview/recarbrio-epar-medicine-overview_pt.pdf)

română (RO) (175.2 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/ro/documents/overview/recarbrio-epar-medicine-overview_ro.pdf)

slovenčina (SK) (181.22 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/sk/documents/overview/recarbrio-epar-medicine-overview_sk.pdf)

slovenščina (SL) (177.46 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/sl/documents/overview/recarbrio-epar-medicine-overview_sl.pdf)

Suomi (FI) (154.82 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/fi/documents/overview/recarbrio-epar-medicine-overview_fi.pdf)

svenska (SV) (156.25 KB - PDF)

**First published:**

26/02/2020

**Last updated:**

19/02/2021

[View](/sv/documents/overview/recarbrio-epar-medicine-overview_sv.pdf)

Recarbrio : EPAR - Risk-management-plan summary

English (EN) (1.62 MB - PDF)

**First published:** 26/02/2020

**Last updated:** 18/01/2021

[View](/en/documents/rmp-summary/recarbrio-epar-risk-management-plan-summary_en.pdf)

## Product information

Recarbrio : EPAR - Product information

English (EN) (325.13 KB - PDF)

**First published:** 18/01/2021

**Last updated:** 24/09/2024

[View](/en/documents/product-information/recarbrio-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-197)

български (BG) (342.67 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/bg/documents/product-information/recarbrio-epar-product-information_bg.pdf)

español (ES) (340.99 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/es/documents/product-information/recarbrio-epar-product-information_es.pdf)

čeština (CS) (372.99 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/cs/documents/product-information/recarbrio-epar-product-information_cs.pdf)

dansk (DA) (344.74 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/da/documents/product-information/recarbrio-epar-product-information_da.pdf)

Deutsch (DE) (377.58 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/de/documents/product-information/recarbrio-epar-product-information_de.pdf)

eesti keel (ET) (345.02 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/et/documents/product-information/recarbrio-epar-product-information_et.pdf)

ελληνικά (EL) (338.78 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/el/documents/product-information/recarbrio-epar-product-information_el.pdf)

français (FR) (372.71 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/fr/documents/product-information/recarbrio-epar-product-information_fr.pdf)

hrvatski (HR) (351 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/hr/documents/product-information/recarbrio-epar-product-information_hr.pdf)

íslenska (IS) (331.59 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/is/documents/product-information/recarbrio-epar-product-information_is.pdf)

italiano (IT) (347.92 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/it/documents/product-information/recarbrio-epar-product-information_it.pdf)

latviešu valoda (LV) (328.25 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/lv/documents/product-information/recarbrio-epar-product-information_lv.pdf)

lietuvių kalba (LT) (365.35 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/lt/documents/product-information/recarbrio-epar-product-information_lt.pdf)

magyar (HU) (400.45 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/hu/documents/product-information/recarbrio-epar-product-information_hu.pdf)

Malti (MT) (381.77 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/mt/documents/product-information/recarbrio-epar-product-information_mt.pdf)

Nederlands (NL) (351.41 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/nl/documents/product-information/recarbrio-epar-product-information_nl.pdf)

norsk (NO) (320.05 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/no/documents/product-information/recarbrio-epar-product-information_no.pdf)

polski (PL) (395.97 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/pl/documents/product-information/recarbrio-epar-product-information_pl.pdf)

português (PT) (350.9 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/pt/documents/product-information/recarbrio-epar-product-information_pt.pdf)

română (RO) (347.4 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/ro/documents/product-information/recarbrio-epar-product-information_ro.pdf)

slovenčina (SK) (380.27 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/sk/documents/product-information/recarbrio-epar-product-information_sk.pdf)

slovenščina (SL) (376.5 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/sl/documents/product-information/recarbrio-epar-product-information_sl.pdf)

Suomi (FI) (345.51 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/fi/documents/product-information/recarbrio-epar-product-information_fi.pdf)

svenska (SV) (328.89 KB - PDF)

**First published:**

18/01/2021

**Last updated:**

24/09/2024

[View](/sv/documents/product-information/recarbrio-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0029 30/01/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Recarbrio : EPAR - All authorised presentations

English (EN) (52.49 KB - PDF)

**First published:** 26/02/2020

[View](/en/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-620)

български (BG) (53.68 KB - PDF)

**First published:**

26/02/2020

[View](/bg/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_bg.pdf)

español (ES) (50.71 KB - PDF)

**First published:**

26/02/2020

[View](/es/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_es.pdf)

čeština (CS) (52.31 KB - PDF)

**First published:**

26/02/2020

[View](/cs/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (52.09 KB - PDF)

**First published:**

26/02/2020

[View](/da/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (52.72 KB - PDF)

**First published:**

26/02/2020

[View](/de/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (50.52 KB - PDF)

**First published:**

26/02/2020

[View](/et/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (52.98 KB - PDF)

**First published:**

26/02/2020

[View](/el/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_el.pdf)

français (FR) (50.71 KB - PDF)

**First published:**

26/02/2020

[View](/fr/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (51.03 KB - PDF)

**First published:**

26/02/2020

[View](/hr/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (51.6 KB - PDF)

**First published:**

26/02/2020

[View](/is/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_is.pdf)

italiano (IT) (50.43 KB - PDF)

**First published:**

26/02/2020

[View](/it/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (51.91 KB - PDF)

**First published:**

26/02/2020

[View](/lv/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (51.56 KB - PDF)

**First published:**

26/02/2020

[View](/lt/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (51.46 KB - PDF)

**First published:**

26/02/2020

[View](/hu/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (58.3 KB - PDF)

**First published:**

26/02/2020

[View](/mt/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (51.17 KB - PDF)

**First published:**

26/02/2020

[View](/nl/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (52.39 KB - PDF)

**First published:**

26/02/2020

[View](/no/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_no.pdf)

polski (PL) (52.66 KB - PDF)

**First published:**

26/02/2020

[View](/pl/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_pl.pdf)

português (PT) (51.88 KB - PDF)

**First published:**

26/02/2020

[View](/pt/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_pt.pdf)

română (RO) (51.23 KB - PDF)

**First published:**

26/02/2020

[View](/ro/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (52.27 KB - PDF)

**First published:**

26/02/2020

[View](/sk/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (50.93 KB - PDF)

**First published:**

26/02/2020

[View](/sl/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (51.53 KB - PDF)

**First published:**

26/02/2020

[View](/fi/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (51.09 KB - PDF)

**First published:**

26/02/2020

[View](/sv/documents/all-authorised-presentations/recarbrio-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Recarbrio Active substance

- imipenem monohydrate
- cilastatin sodium
- relebactam monohydrate

International non-proprietary name (INN) or common name

- imipenem
- cilastatin
- relebactam

Therapeutic area (MeSH) Gram-Negative Bacterial Infections Anatomical therapeutic chemical (ATC) code J01DH56

### Pharmacotherapeutic group

- Antibacterials for systemic use
- Carbapenems

### Therapeutic indication

Recarbrio is indicated for:

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

## Authorisation details

EMA product number EMEA/H/C/004808 Marketing authorisation holder

Merck Sharp &amp; Dohme B.V.

Waarderweg 39 2031 BN Haarlem The Netherlands

Opinion adopted 12/12/2019 Marketing authorisation issued 13/02/2020 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Recarbrio : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (185.63 KB - PDF)

**First published:** 18/01/2021

**Last updated:** 24/09/2024

[View](/en/documents/procedural-steps-after/recarbrio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Recarbrio-H-C-4808-P46-005 : EPAR - Assessment report

Reference Number: EMA/70482/2025

English (EN) (2.5 MB - PDF)

**First published:** 07/03/2025

[View](/en/documents/variation-report/recarbrio-h-c-4808-p46-005-epar-assessment-report_en.pdf)

Recarbrio-H-C-4808-P46-003 : EPAR - Assessment report

Reference Number: EMA/265651/2021

English (EN) (673.81 KB - PDF)

**First published:** 18/05/2021

[View](/en/documents/variation-report/recarbrio-h-c-4808-p46-003-epar-assessment-report_en.pdf)

Recarbrio-H-C-4808-II-0001 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/538608/2020

English (EN) (3.08 MB - PDF)

**First published:** 19/01/2021

[View](/en/documents/variation-report/recarbrio-h-c-4808-ii-0001-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Recarbrio (II-01)

Adopted

Reference Number: EMA/CHMP/537033/2020

English (EN) (146.01 KB - PDF)

**First published:** 16/10/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-recarbrio-ii-01_en.pdf)

## Initial marketing authorisation documents

Recarbrio : EPAR - Public assessment report

Adopted

Reference Number: EMA/7621/2020

English (EN) (5.76 MB - PDF)

**First published:** 26/02/2020

[View](/en/documents/assessment-report/recarbrio-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Recarbrio

Adopted

Reference Number: EMA/CHMP/662007/2019

English (EN) (137.52 KB - PDF)

**First published:** 13/12/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-recarbrio_en.pdf)

#### News on Recarbrio

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020) 16/10/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2019) 13/12/2019

#### More information on Recarbrio

- [EMEA-001809-PIP01-15-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001809-pip01-15-m05)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 07/03/2025

## Share this page

[Back to top](#main-content)